BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 16858170)

  • 1. Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.
    Bao T; Prowell T; Stearns V
    Am J Ther; 2006; 13(4):337-48. PubMed ID: 16858170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
    Vogel VG
    Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hormone-related cancers: breast cancer.
    Dunn BK; Wickerham DL; Ford LG
    J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC
    Eur J Cancer; 2006 Nov; 42(17):2909-13. PubMed ID: 17064889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventive therapy for breast cancer: a consensus statement.
    Cuzick J; DeCensi A; Arun B; Brown PH; Castiglione M; Dunn B; Forbes JF; Glaus A; Howell A; von Minckwitz G; Vogel V; Zwierzina H
    Lancet Oncol; 2011 May; 12(5):496-503. PubMed ID: 21441069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current concepts in breast cancer chemoprevention.
    Chlebowski RT
    Pol Arch Med Wewn; 2014; 124(4):191-9. PubMed ID: 24618912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of breast cancer: current state of the science and future opportunities.
    Uray IP; Brown PH
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1583-600. PubMed ID: 17107283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
    Visvanathan K; Chlebowski RT; Hurley P; Col NF; Ropka M; Collyar D; Morrow M; Runowicz C; Pritchard KI; Hagerty K; Arun B; Garber J; Vogel VG; Wade JL; Brown P; Cuzick J; Kramer BS; Lippman SM;
    J Clin Oncol; 2009 Jul; 27(19):3235-58. PubMed ID: 19470930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention of breast cancer in the older patient.
    Minton SE
    Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer chemoprevention.
    Rosenbaum Smith SM; Osborne MP
    Am J Surg; 2000 Oct; 180(4):249-51. PubMed ID: 11113429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
    Dickler MN; Norton L
    Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
    Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
    Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
    Zujewski J
    Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prevention of breast cancer: new approaches.
    Cummings SR
    Maturitas; 2007 May; 57(1):39-41. PubMed ID: 17391879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen to raloxifene and beyond.
    O'Regan RM; Jordan VC
    Semin Oncol; 2001 Jun; 28(3):260-73. PubMed ID: 11402436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.